I-Mab Shifts Focus Away from CD73 Program to Pursue Strategic Options in CLDN18.2 Space

Program Pause:
I-Mab has halted the development of its CD73 program, which was partnered with Sanofi, to focus on other strategic options, including the CLDN18.2 space5.

Strategic Shift:
This decision reflects a strategic shift in I-Mab’s pipeline priorities, emphasizing the potential of other projects like givastomig5.

Previous Collaboration:
I-Mab and Sanofi had a collaboration agreement for the development and commercialization of uliledlimab (a CD73 antibody) in Greater China, with I-Mab holding worldwide rights outside of this region1.

Financial Impact:
The pause in the CD73 program may have implications for I-Mab’s financial projections, although the company has a strong cash balance and an estimated cash runway into 20271.

Future Directions:
I-Mab is now focusing on advancing other pipeline projects, including givastomig and ragistomig, with encouraging data presented at international medical conferences1.

Sources:

1. https://www.biospace.com/press-releases/i-mab-reports-third-quarter-2024-results

5. https://endpts.com/i-mab-stops-work-on-cd73-citius-to-pursue-strategic-options/